CN109942497A - Polysubstituted pyrimidone compound and preparation method thereof - Google Patents

Polysubstituted pyrimidone compound and preparation method thereof Download PDF

Info

Publication number
CN109942497A
CN109942497A CN201910371655.2A CN201910371655A CN109942497A CN 109942497 A CN109942497 A CN 109942497A CN 201910371655 A CN201910371655 A CN 201910371655A CN 109942497 A CN109942497 A CN 109942497A
Authority
CN
China
Prior art keywords
reaction
additive
preparation
ruthenium
reaction tube
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910371655.2A
Other languages
Chinese (zh)
Inventor
胡绪红
史鹏飞
刘瑞华
李松
胡路敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Tech University
Original Assignee
Nanjing Tech University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Tech University filed Critical Nanjing Tech University
Priority to CN201910371655.2A priority Critical patent/CN109942497A/en
Publication of CN109942497A publication Critical patent/CN109942497A/en
Pending legal-status Critical Current

Links

Landscapes

  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a polysubstituted pyrimidone compound, which has a structure shown as the following formula:the preparation method comprises the following steps of respectively adding substituted enamide, isocyanate, a ruthenium catalyst, an additive I and an additive II into a Schlenk reaction tube under the protection of nitrogen; replacing the reaction tube with nitrogen for 3 times, adding 2mL of solvent into the reaction tube by using an injector under the protection of nitrogen, and heating and stirring; after the reaction of the reaction solution is finished, cooling the reaction solution to room temperature, quenching the reaction solution by using 10mL of saturated sodium bicarbonate solution, and extracting the reaction solution for 3 times by using 10mL of dichloromethane; the organic phases were combined and washed with anhydrous Na2SO4The new synthetic route of the pyrimidone compound provided by the invention has the advantages of high efficiency, atom economy, mild reaction conditions, wide substrate application range and the like, and has potential application prospect in the field of drug synthesis.

Description

A kind of polysubstituted pyrimidine ketone compound and preparation method thereof
Technical field
The present invention relates to organic chemical synthesis technical field, specially a kind of polysubstituted pyrimidine ketone compound and its preparation side Method.
Background technique
Pyrimidone is a kind of highly important nitrogen-containing heterocycle compound, is widely present in biologically active drug molecule In functional material.As the basic structural unit of base in hereditary material DNA and RNA, pyrimidone is in biological medicine and pesticide Synthesis also plays indispensable role in field.For example, Muconorm (antihistamine), (cognition assists sapropterin Medicine), Allopurinol (treatment goat) and Lamivudine (antiviral agent) be using pyrimidone as precursor structure, in addition, this kind ofization Close object also have anti-cancer (ACS Med.Chem.Lett.2018,9,238-243.), blood pressure lowering (J.Med.Chem.1995, 38,4806-4820), important bioactivity such as antimycotic (Bioorg.Med.Chem.Lett.2003,13,1713-1716).
The method of synthesis pyrimidinone compound includes: (1) A.Pinner anti-using β-carbonyl ester and amidine generation condensation at present It answers, but reaction time consumption is long, conversion ratio is lower, and substrate spectrum is relatively narrow;(2) M.P.Mahajan utilizes 1,3- diaza -1,3- fourth two [4+2] cycloaddition reaction occurs for alkene and ketenes, but raw material is not easy to prepare, and reacts and generate a large amount of wastes;(3) with β-carbonyl ester Or beta-amino ester is raw material, constructs pyrimidone skeleton, this method complex steps by multistep reaction, and reaction selectivity is lower. Therefore, it is polysubstituted still to lack a kind of efficient, Atom economy, mild condition, wide application range of substrates method synthesis for this field Pyrimidinone compound.
Summary of the invention
The purpose of the present invention is to provide a kind of polysubstituted pyrimidine ketone compounds and preparation method thereof to solve above-mentioned background The problem of being proposed in technology.
To achieve the above object, the invention provides the following technical scheme: a kind of polysubstituted pyrimidine ketone compound, structure is such as Shown under formula:
In formula, R1For p-trifluoromethyl phenyl, 1,2- methylene dioxy phenyl group, p-methylphenyl, to cyano benzene Base, m-methoxyphenyl, p-bromophenyl, o-fluorophenyl, 2- naphthalene, tert-butyl, 2- thienyl, p-fluorophenyl, rubigan, 3, 4- ihydro naphthyl, adamantyl;R2For methyl, ethyl, propyl, isobutyl group, cyclohexyl, styryl;R3For p-methylphenyl, neighbour Tolyl, normal-butyl, Chloro-O-Phenyl, ethyl, cyclohexyl, rubigan, tolyl, p-methoxyphenyl, benzyl, to fluorobenzene Base, 1- naphthalene, p-trifluoromethyl phenyl, acetylphenyl, to cyano-phenyl, n-octyl.
The present invention also provides the preparation methods of above-mentioned polysubstituted pyrimidine ketone compound, comprising the following steps:
(1) under nitrogen protection, to the substitution alkene for being separately added into 0.45~0.75mmol in the Schlenk reaction tube of 10mL Amide, the isocyanates of 0.3mmol, the ruthenium catalyst of 5mol%, the additive one of 20mol% and the additive of 0.45mmol Two;
(2) with nitrogen displacement reaction tube 3 times, and under nitrogen protection, the molten of 2mL is added into reaction tube with syringe Agent, and carry out heating and stirring, and be heated to 60~120 DEG C, mixing time is 12~for 24 hours;
(3) when the reaction solution in (2) after reaction, reaction solution is cooled to room temperature, it is molten with 10mL saturated sodium bicarbonate Liquid is quenched, then is extracted 3 times with 10mL methylene chloride;
(4) merge organic phase, and use anhydrous Na2SO4It dry half an hour, is then filtered and is concentrated, then use silica gel Column chromatography carries out isolated net product.
Specifically, described to replace acrylamide, isocyanates, ruthenium catalyst, additive one, additive two and organic solvent Molal volume ratio corresponds to 1.5~2.5mmol:1.0mmol:0.05mmol:0.2mmol:0.45mmol:2mL respectively.
Specifically, the solvent is non-protonic solvent, and solvent is acetonitrile, Isosorbide-5-Nitrae-dioxane, chlorobenzene, tetrahydro furan It mutters, one of methylene chloride, 1,2- tetrachloroethanes, toluene.
Specifically, the ruthenium catalyst is that ten dicarbapentaborane, three ruthenium, hydrate ruthenium trichloride, acetylacetone,2,4-pentanedione ruthenium, dichloro are bis- (to first Base isopropyl phenyl) one of ruthenium dimer and (1,5- cyclo-octadiene) ruthenous chloride.
Specifically, the additive one is silver trifluoromethanesulfonate, silver acetate, silver tetrafluoroborate, silver hexafluoroantimonate and double three One of fluorine methylsulfonimide silver.
Specifically, the additive two is organic acid, such as acetic acid, trifluoroacetic acid, pivalic acid, adamantanecarboxylic acid, benzene first One of acid, 2,4,6- trimethylbenzoic acid, 2,6- mesitylenic acid and salicylic acid.
Compared with prior art, the beneficial effects of the present invention are:
(1) present invention is selected using ruthenium catalyst homogeneous catalysis acrylamide by site under relatively mild reaction condition Property carbon-hydrogen bond activation, concatenated amine acylation/cyclization occurs with isocyanates, quickly and easily building contains multiple substituent groups Pyrimidone skeleton, reactive chemistry formula is as follows:
(2) by (1) it is found that participating in reaction process without oxidant, and reaction condition is mild, from raw material and product From the point of view of structure, harmless water is only generated as byproduct, there is good Atom economy.
(3) in the preparation, raw material used includes that acrylamide and isocyanates are all cheap and easy to get, compared to traditional multistep road Line, synthesis step are simpler;Compared with Pinner condensation method, the reaction condition milder, the reaction time is short, and higher yields obtain To target product.
(4) under the catalysis of transition metal ruthenium, acrylamide as homing device, Selective activation acrylamide it is cis- hydrocarbon Key generates C (sp2)-Ru intermediate, nucleophilic addition, further cyclodehydration occurs with isocyanates.
(5) preparation method of pyrimidinone compound provided by the invention has good regioselectivity, functional group's tolerance Property it is good, by introducing different substituent groups in substrate, can with a step construct polysubstituted pyrimidine ketone compound.
Therefore, the new synthesis route that the present invention provides pyrimidinone compound has efficient, Atom economy, reaction condition temperature With and the advantages that wide application range of substrates, there is potential application prospect in pharmaceutical synthesis field.
Detailed description of the invention
Fig. 1 is the nuclear magnetic resonance of 2- methyl -6- phenyl -3- (p-methylphenyl) pyrimidine -4 (3H) -one in the embodiment of the present invention 1 Hydrogen spectrogram;
Fig. 2 is the nuclear magnetic resonance of 2- methyl -6- phenyl -3- (p-methylphenyl) pyrimidine -4 (3H) -one in the embodiment of the present invention 1 Carbon spectrogram;
Fig. 3 is the nuclear magnetic resonance of -4 (3H) -one of 2- methyl -3- p-methylphenyl -6- t-butyl pyrimidines in the embodiment of the present invention 8 Hydrogen spectrogram;
Fig. 4 is the nuclear magnetic resonance of -4 (3H) -one of 2- methyl -3- p-methylphenyl -6- t-butyl pyrimidines in the embodiment of the present invention 8 Carbon spectrogram.
Specific embodiment
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete Site preparation description, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts every other Embodiment shall fall within the protection scope of the present invention.
Embodiment one
The synthesis of 2- methyl -6- phenyl -3- (p-methylphenyl) pyrimidine -4 (3H) -one:
Under nitrogen protection, to addition N- (1- phenyl vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 120.9mg), (p -Methylisopropylbenzene base) ruthenium bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated white solid of silica gel column chromatography;Yield is 83%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.04-7.98 (m, 2H), 7.51- 7.46 (m, 3H), 7.39-7.34 (m, 2H), 7.14 (d, J=8.3Hz, 2H), 6.89 (s, 1H), 2.44 (s, 3H), 2.28 (s, 3H)。
Embodiment two
The synthesis of -4 (3H) -one of 2- methyl -3,6- di-p-tolyl pyrimidine:
Under nitrogen protection, to addition N- (1- p-methylphenyl vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 131.4mg), (p -Methylisopropylbenzene base) ruthenium bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated white solid of silica gel column chromatography;Yield is 50%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 7.91 (d, J=8.2Hz, 2H), 7.40-7.34 (m, 2H), 7.31-7.26 (m, 2H), 7.14 (d, J=8.3Hz, 2H), 6.86 (s, 1H), 2.44 (s, 3H), 2.42 (s, 3H), 2.27 (s, 3H).
Embodiment three
Synthesis of the 2- methyl -3- p-methylphenyl -6- to cyano-phenyl pyrimidine -4 (3H) -one:
Under nitrogen protection, to addition N- (1- is to cyano-phenyl vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 139.7mg), (p -Methylisopropylbenzene base) ruthenium bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.4mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, adds Heat stirs 16h to 100 DEG C;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, then It is extracted 3 times with 10mL methylene chloride;Merge organic phase and uses anhydrous Na2SO4It dry half an hour, is then filtered and is concentrated, And using the net product of the isolated yellow solid of silica gel column chromatography;Yield is 70%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.14-8.07 (m, 2H), 7.81- 7.71 (m, 2H), 7.37 (d, J=8.2Hz, 2H), 7.17-7.08 (m, 2H), 6.91 (s, 1H), 2.44 (s, 3H), 2.28 (s, 3H)。
Example IV
The synthesis of -4 (3H) -one of 2- methyl -3- p-methylphenyl -6- rubigan pyrimidine:
Under nitrogen protection, to addition N- (1- rubigan vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 146.7mg), (p -Methylisopropylbenzene base) ruthenium bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated white solid of silica gel column chromatography;Yield is 98%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 7.95 (d, J=8.5Hz, 2H), 7.45 (d, J=8.6Hz, 2H), 7.36 (dt, J=8.5,0.7Hz, 2H), 7.13 (d, J=8.2Hz, 2H), 6.85 (s, 1H), 2.44 (s, 3H), 2.27 (s, 3H).
Embodiment five
The synthesis of 2- methyl -3- p-methylphenyl -6- (2- fluorophenyl) pyrimidine -4 (3H) -one:
Under nitrogen protection, to addition N- (1- (2- fluorophenyl) vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 134.4mg), (p -Methylisopropylbenzene base) ruthenium bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 120 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated light yellow solid of silica gel column chromatography;Yield is 54%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.09 (td, J=7.9,2.0Hz, 1H), 7.46-7.38 (m, 1H), 7.36 (d, J=8.0Hz, 2H), 7.30-7.24 (m, 1H), 7.16-7.13 (m, 3H), 7.03 (s, 1H), 2.43 (s, 3H), 2.26 (s, 3H).
Embodiment six
The synthesis of 2- methyl -3- p-methylphenyl -6- (3- methoxyphenyl) pyrimidine -4 (3H) -one:
Under nitrogen protection, to addition N- (1- (3- methoxyphenyl) vinyl) acetyl in 10mL Schlenk reaction tube Amine (0.75mmol, 143.4mg), (p -Methylisopropylbenzene bases) bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Ruthenium dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated white solid of silica gel column chromatography;Yield is 53%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 7.57 (dt, J=5.0,1.8Hz, 2H), 7.43-7.33 (m, 3H), 7.14 (d, J=8.2Hz, 2H), 7.02 (ddd, J=8.2,2.6,1.0Hz, 1H), 6.87 (s, 1H), 3.88 (s, 3H), 2.44 (s, 3H), 2.27 (s, 3H).
Embodiment seven
The synthesis of 2- methyl -3- p-methylphenyl -6- (2- naphthalene) pyrimidine -4 (3H) -one:
Under nitrogen protection, to addition N- (1- (3- methoxyphenyl) vinyl) acetyl in 10mLSchlenk reaction tube Amine (0.75mmol, 158.4mg), (p -Methylisopropylbenzene bases) bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Ruthenium dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 1mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated light yellow solid of silica gel column chromatography;Yield is 87%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.64-8.59 (m, 1H), 8.04 (dd, J=8.6,1.8Hz, 1H), 8.00-7.85 (m, 3H), 7.58-7.52 (m, 2H), 7.38 (dt, J=7.8,0.7Hz, 2H), 7.17 (d, J=8.3Hz, 2H), 7.04 (s, 1H), 2.45 (s, 3H), 2.33 (s, 3H).
Embodiment eight
The synthesis of -4 (3H) -one of 2- methyl -3- p-methylphenyl -6- t-butyl pyrimidines:
Under nitrogen protection, to addition N- (1- tert-butyl vinyl base) acetamide in 10mL Schlenk reaction tube (0.75mmol, 105.9mg), (p -Methylisopropylbenzene base) ruthenium bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated white solid of silica gel column chromatography;Yield is 64%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 7.36-7.28 (m, 2H), 7.09 (d, J=8.3Hz, 2H), 6.41 (s, 1H), 2.41 (s, 3H), 2.16 (s, 3H), 1.28 (s, 9H).
Embodiment nine
The synthesis of -4 (3H) -one of 2- ethyl -3- p-methylphenyl -6- phenyl pyrimidine:
Under nitrogen protection, to addition N- (1- phenyl vinyl) propionamide in 10mL Schlenk reaction tube (0.75mmol, 131.4mg), (p -Methylisopropylbenzene base) ruthenium bis- to toluene diisocyanate (0.3mmol, 40.0mg), dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated light yellow solid of silica gel column chromatography;Yield is 91%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.08 (dd, J=6.8,2H), 7.49 (dd, J=4.8,3H), 7.36 (d, J=8.1Hz, 2H), 7.19-7.09 (m, 2H), 6.92 (s, 1H), 2.49-2.43 (m, 5H), 1.28 (t, J=7.3Hz, 3H).
Embodiment ten
The synthesis of 2- methyl -3- (4- methoxyphenyl) -6- phenyl pyrimidine -4 (3H) -one:
Under nitrogen protection, to addition N- (1- phenyl vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 131.4mg), 4- methoxybenzene isocyanates (0.3mmol, 44.7mg), the bis- (p -Methylisopropylbenzenes of dichloro Base) ruthenium dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated light yellow solid of silica gel column chromatography;Yield is 84%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.04-7.97 (m, 2H), 7.50- 7.45 (m, 3H), 7.17 (d, J=8.9Hz, 2H), 7.05 (d, J=8.9Hz, 2H), 6.88 (s, 1H), 3.85 (s, 3H), 2.27 (s, 3H).
Embodiment 11
The synthesis of 2- methyl -3- (3- bromophenyl) -6- phenyl pyrimidine -4 (3H) -one:
Under nitrogen protection, to addition N- (1- phenyl vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 131.4mg), 3- bromobenzene isocyanates (0.3mmol, 59.4mg), bis- (p -Methylisopropylbenzene base) rutheniums of dichloro Dimer (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, 100 DEG C are heated to, 16h is stirred;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, It is extracted 3 times with 10mL methylene chloride again;Merge organic phase and uses anhydrous Na2SO4Dry half an hour, be then filtered with it is dense Contracting, and using the net product of the isolated light tan solid of silica gel column chromatography;Yield is 85%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.04-7.97 (m, 2H), 7.66 (ddd, J=8.1,1.9,1.0Hz, 1H), 7.52-7.42 (m, 5H), 7.23 (ddd, J=7.9,2.0,1.0Hz, 1H), 6.88 (s, 1H), 2.29 (s, 3H).
Embodiment 12
The synthesis of -4 (3H) -one of 2- methyl -3- benzyl -6- phenyl pyrimidine:
Under nitrogen protection, to addition N- (1- phenyl vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 131.4mg), benzyl mustard oil (0.3mmol, 40.0mg), bis- (p -Methylisopropylbenzene base) the ruthenium dimerization of dichloro Body (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, is heated to 100 DEG C, stir 16h;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, then use 10mL Methylene chloride extracts 3 times;Merge organic phase and uses anhydrous Na2SO4It dry half an hour, is then filtered and is concentrated, and use The net product of the isolated white solid of silica gel column chromatography;Yield is 72%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 8.02-7.96 (m, 2H), 7.50- 7.44 (m, 3H), 7.39-7.32 (m, 2H), 7.32-7.28 (m, 1H), 7.25-7.21 (m, 2H), 6.88 (s, 1H), 5.35 (s, 2H), 2.55 (s, 3H).
Embodiment 13
The synthesis of -4 (3H) -one of 2- methyl -3- ethyl -6- phenyl pyrimidine:
Under nitrogen protection, to addition N- (1- phenyl vinyl) acetamide in 10mL Schlenk reaction tube (0.75mmol, 131.4mg), ethyl isocyanate (0.3mmol, 21.3mg), bis- (p -Methylisopropylbenzene base) the ruthenium dimerization of dichloro Body (0.015mmol, 9.2mg), silver hexafluoroantimonate (0.06mmol, 20.9mg), 2,4,6- trimethylbenzoic acids (0.45mmol, 73.9mg);2mL tetrahydrofuran is added with syringe with nitrogen displacement reaction tube 3 times, and under nitrogen protection, is heated to 100 DEG C, stir 16h;After reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution, then use 10mL Methylene chloride extracts 3 times;Merge organic phase and uses anhydrous Na2SO4It dry half an hour, is then filtered and is concentrated, and use The net product of the isolated white solid of silica gel column chromatography;Yield is 66%.
The nucleus magnetic hydrogen spectrum data of the product are as follows:1H NMR (400MHz, CDCl3): δ 7.96-7.90 (m, 2H), 7.47- 7.41 (m, 3H), 6.75 (s, 1H), 4.11 (q, J=7.2Hz, 2H), 2.64 (s, 3H), 1.35 (t, J=7.2Hz, 3H).
Although the present invention is described in detail referring to the foregoing embodiments, for those skilled in the art, It is still possible to modify the technical solutions described in the foregoing embodiments, or part of technical characteristic is carried out etc. With replacement, all within the spirits and principles of the present invention, any modification, equivalent replacement, improvement and so on should be included in this Within the protection scope of invention.

Claims (7)

1. a kind of polysubstituted pyrimidine ketone compound, it is characterised in that: shown under its structure such as formula:
In formula, R1For p-trifluoromethyl phenyl, 1,2- methylene dioxy phenyl group, p-methylphenyl, to cyano-phenyl, m-methoxyphenyl, P-bromophenyl, o-fluorophenyl, 2- naphthalene, tert-butyl, 2- thienyl, p-fluorophenyl, rubigan, 3,4- ihydro naphthyl, Buddha's warrior attendant Alkyl;R2For methyl, ethyl, propyl, isobutyl group, cyclohexyl, styryl;R3For p-methylphenyl, o-tolyl, normal-butyl, neighbour Chlorphenyl, ethyl, cyclohexyl, rubigan, tolyl, p-methoxyphenyl, benzyl, p-fluorophenyl, 1- naphthalene, to trifluoro Aminomethyl phenyl, acetylphenyl, to cyano-phenyl, n-octyl.
2. the preparation method of polysubstituted pyrimidine ketone compound according to claim 1, it is characterised in that: including following step It is rapid:
(1) under nitrogen protection, to the substitution alkene acyl for being separately added into 0.45~0.75mmol in the Schlenk reaction tube of 10mL Amine, the isocyanates of 0.3mmol, the ruthenium catalyst of 5mol%, the additive one of 20mol% and 0.45mmol additive two;
(2) with nitrogen displacement reaction tube 3 times, and under nitrogen protection, the solvent of 2mL is added into reaction tube with syringe, and Heating and stirring are carried out, and are heated to 60~120 DEG C, mixing time is 12~for 24 hours;
(3) when the reaction solution in (2) after reaction, reaction solution is cooled to room temperature, is quenched with 10mL saturated sodium bicarbonate solution It goes out, then is extracted 3 times with 10mL methylene chloride;
(4) merge organic phase, and use anhydrous Na2SO4It dry half an hour, is then filtered and is concentrated, then use silica gel column layer Analysis carries out isolated net product.
3. the preparation method of polysubstituted pyrimidine ketone compound according to claim 2, it is characterised in that: the substitution alkene acyl Amine, isocyanates, ruthenium catalyst, additive one, additive two and organic solvent molal volume than correspond to 1.5 respectively~ 2.5mmol:1.0mmol:0.05mmol:0.2mmol:0.45mmol:2mL.
4. the preparation method of polysubstituted pyrimidine ketone compound according to claim 2, it is characterised in that: the solvent is non- Protonic solvent, and solvent is acetonitrile, Isosorbide-5-Nitrae-dioxane, chlorobenzene, tetrahydrofuran, methylene chloride, 1,2- tetrachloroethanes, toluene One of.
5. the preparation method of polysubstituted pyrimidine ketone compound according to claim 2, it is characterised in that: the ruthenium catalyst For bis- (p -Methylisopropylbenzene base) the ruthenium dimers of ten dicarbapentaborane, three ruthenium, hydrate ruthenium trichloride, acetylacetone,2,4-pentanedione ruthenium, dichloro and (1, One of 5- cyclo-octadiene) ruthenous chloride.
6. the preparation method of polysubstituted pyrimidine ketone compound according to claim 2, it is characterised in that: the additive one For one of silver trifluoromethanesulfonate, silver acetate, silver tetrafluoroborate, silver hexafluoroantimonate and bis-trifluoromethylsulfoandimide silver.
7. the preparation method of polysubstituted pyrimidine ketone compound according to claim 2, it is characterised in that: the additive two For organic acid, such as acetic acid, trifluoroacetic acid, pivalic acid, adamantanecarboxylic acid, benzoic acid, 2,4,6- trimethylbenzoic acid, 2,6- bis- One of methyl benzoic acid and salicylic acid.
CN201910371655.2A 2019-05-06 2019-05-06 Polysubstituted pyrimidone compound and preparation method thereof Pending CN109942497A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910371655.2A CN109942497A (en) 2019-05-06 2019-05-06 Polysubstituted pyrimidone compound and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910371655.2A CN109942497A (en) 2019-05-06 2019-05-06 Polysubstituted pyrimidone compound and preparation method thereof

Publications (1)

Publication Number Publication Date
CN109942497A true CN109942497A (en) 2019-06-28

Family

ID=67016949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910371655.2A Pending CN109942497A (en) 2019-05-06 2019-05-06 Polysubstituted pyrimidone compound and preparation method thereof

Country Status (1)

Country Link
CN (1) CN109942497A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563270A (en) * 2021-08-10 2021-10-29 苏州小栗医药科技有限公司 Synthetic method of 2-bromopyrimidine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570630A (en) * 2012-07-18 2014-02-12 广东东阳光药业有限公司 Heterocyclic nitrogen derivative and application thereof in medicines
CN104725356A (en) * 2013-12-19 2015-06-24 广东东阳光药业有限公司 Nitrogen heterocyclic derivatives and application thereof in medicine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570630A (en) * 2012-07-18 2014-02-12 广东东阳光药业有限公司 Heterocyclic nitrogen derivative and application thereof in medicines
CN104725356A (en) * 2013-12-19 2015-06-24 广东东阳光药业有限公司 Nitrogen heterocyclic derivatives and application thereof in medicine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KEVIN D. HESP ET AL: "Expedient Synthesis of N-Acyl Anthranilamides and β-Enamine Amides by the Rh(III)-Catalyzed Amidation of Aryl and Vinyl C-H Bonds with Isocyanates", 《JOURNAL OF THE AMERICAN CHEMICAL OF SOCIETY》 *
田明晴 等: "Divergent C − H Oxidative Radical Functionalization of Olefns to Install a Tertiary Alkyl Motifs Enabled by Copper Catalysis", 《THE 2ND NATIONAL ORGANIC RADICAL CHEMISTRY SYMPOSIUM OF CHINA》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563270A (en) * 2021-08-10 2021-10-29 苏州小栗医药科技有限公司 Synthetic method of 2-bromopyrimidine

Similar Documents

Publication Publication Date Title
CN104926811B (en) The synthetic method of 3-cyanoimidazole also [1,2-a] pyridine compounds and application thereof
Song et al. Asymmetric synthesis of highly functionalized spirothiazolidinone tetrahydroquinolines via a squaramide-catalyzed cascade reaction
CN109942497A (en) Polysubstituted pyrimidone compound and preparation method thereof
JP2007230963A (en) Method for producing 2,4-disubstituted pyridine
CN101195626A (en) Method for synthesizing pyrazole [3,4-d] pyrimidine-4(5H)-ketone compounds
CN111925356A (en) Synthesis method and application of chiral quinoline-imidazoline ligand
CN105820174A (en) Polysubstituted thienoindole derivative and preparation method thereof
CN111592509B (en) Method for synthesizing aryl (3-sulfuryl benzofuran-2-yl) ketone compound by copper catalysis
CN113173877B (en) Indole acetyl imino sulfone series compounds and preparation method thereof
Saidalimu et al. Activation of Trifluoromethylthio Moiety by Appending Iodonium Ylide under Copper Catalysis for Electrophilic Trifluoromethylation Reaction
CN105481865B (en) A kind of preparation method of pyrimido [1,6-a] indole Hete rocyclic derivatives
AU2006312801A1 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
CN112625020B (en) Synthesis of isocoumarin derivative by carbon-hydrogen bond activation reaction under catalysis of rhodium
CN109400629B (en) Indole spirooxazine heterocyclic compound and preparation method thereof
CN103755715B (en) Cumarone is [2,3-c] pyridine compounds and synthetic method thereof also
Ichikawa et al. Synthesis of 4-Aryl-1H-pyrazoles by Suzuki-Miyaura cross coupling reaction between 4-Bromo-1H-1-tritylpyrazole and arylboronic acids
CN113429409A (en) Sulfur-containing polysubstituted indolizine compound and preparation method thereof
CN113912609A (en) Preparation method of natural alkaloid tryptanthrin and derivative thereof
CN115557894A (en) Preparation method of allene skeleton-containing chiral dihydropyrazole compound
CN109810069B (en) Preparation method of polysubstituted 1,3, 5-triazine
CN110483430B (en) Preparation method of isoxazole derivative
CN114478361B (en) Method for preparing aza-arene compound by coupling reaction without metal catalysis
CN114181133B (en) Preparation method of glycine derivative acetamide compound
CN103214394B (en) A kind of Alkynyl imine derivative
KR100497105B1 (en) 3,4-Dihydroquinazoline Derivatives and Process for the Preparation Thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190628

RJ01 Rejection of invention patent application after publication